Drugs in R & D

, Volume 4, Issue 6, pp 389–394 | Cite as


SC 54684A, Xemlofiban
Adis R&D Profile


Platelet Aggregation Stent Placement Abciximab Urgent Revascularisation Sibrafiban 


  1. 1.
    Nicholson NS, Panzer-Knodle SG, Salyers AK, et al. SC-54684A: an orally active inhibitor of platelet aggregation. Circulation 91: 403–410, 15 Jan 1995PubMedCrossRefGoogle Scholar
  2. 2.
    Milton MN, Szafon T, Aboayge E. Biliary and renal excretion of SC-54701 in the dog. 7th North American ISSX Meeting 10: 274, 20 Oct 1996Google Scholar
  3. 3.
    Szalony JA, Haas NF, Salyers AK, et al. Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A. Circulation 91: 411–416, 15 Jan 1995PubMedCrossRefGoogle Scholar
  4. 4.
    Higgins G. Three points of attack in fight against restenosis. Inpharma 983: 3–4, 22 April 1995Google Scholar
  5. 5.
    Kereiakes DJ, Kleiman N, Ferguson JJ, et al. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment. Circulation 96: 1117–1121, 19 Aug 1997PubMedCrossRefGoogle Scholar
  6. 6.
    Timmis SBH, Gregory ML, Kleiman JH, et al. Influence of oral glycoprotein IIb/IIIa blockade on bleeding and cardiovascular events in patients undergoing coronary bypass surgery. Circulation 100 (Suppl.): 153, 2 Nov 1999CrossRefGoogle Scholar
  7. 7.
    Umemura K, Nishiyama H, Kikuchi S. Inhibitory effect of GP IIb/IIIa inhibitor, SC-54684A on intima thickening in the guinea pig femoral artery. Japanese Journal of Pharmacology 67 (Suppl. I): 113, 1995Google Scholar
  8. 8.
    Umemura K, Nishiyama H, Kikuchi S, et al. Inhibitory effect of a novel orally active GPIIb/IIIa inhibitor, SC-54684A on intimal thickening in the guinea pig femoral artery. Thrombosis and Haemostasis 76: 799–806, Nov 1996PubMedGoogle Scholar
  9. 9.
    Frederick LG, Suleymanov OD, King LW, et al. The protective dose of the potent GPIIb/IIIa antagonist SC-54701A is reduced when used in combination with aspirin and heparin in a canine model of coronary artery thrombosis. Circulation 93: 129–134, 1 Jan 1996PubMedCrossRefGoogle Scholar
  10. 10.
    Kottke-Marchant K, Simpfendorfer C, Lowrie M. Sustained but variable inhibition of platelet aggregation with xemlofiban, an oral GPIIb/IIIa receptor antagonist, in patients with unstable angina. Circulation 92 (Suppl. I): 488, 15 Oct 1995Google Scholar
  11. 11.
    Kereiakes DJ, Runyon JP, Kleiman NS, et al. Differential doseresponse to oral xemilofiban after antecedent intravenous abciximab: administration for complex coronary intervention. Circulation 94: 906–910, 01 Sep 1996PubMedCrossRefGoogle Scholar
  12. 12.
    Kereiakes DJ, Kleiman NS, Runyon JP, et al. Sustained platelet GP IIb/IIIa blockade with oral xemilofiban: pharmacodynamics and clinical outcomes in 103 patients. Circulation 94 (Suppl.): 256–257, 15 Oct 1996CrossRefGoogle Scholar
  13. 13.
    Simpfendorfer C, Kottke-Marchant K, Lowrie M, et al. First chronic platelet glycoprotein IIb/IIIa integrin blockade: a randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation 96: 76–81, 1 Jul 1997PubMedCrossRefGoogle Scholar
  14. 14.
    Kereiakes DJ, Ferguson JJ, Masud AZ. Sustained platelet Gp Iib/IIIa blockade with oral xemilofiban: final results of the ORBIT Trial. Circulation 96 (Suppl.): 385, 21 Oct 1997CrossRefGoogle Scholar
  15. 15.
    Frederick LG, Suleymanov OD, Szalony JA. Protective effect of oral xemilofiban in arterial thrombosis in dogs: increased activity in combination with aspirin. Circulation 98: 813–820, 25 Aug 1998PubMedCrossRefGoogle Scholar
  16. 16.
    Badimon JJ, Meyer B, Feigen LP, et al. Thrombosis triggered by severe arterial lesions is inhibited by oral administration of a glycoprotein IIb/IIIa antagonist. European Journal of Clinical Investigation 27: 568–574, Jul 1997PubMedCrossRefGoogle Scholar
  17. 17.
    Kleiman NS. Preliminary results of the xemilofiban phase-II ORBIT study in patients undergoing percutaneous coronary revascularization. XIXth Congress of the European Society of Cardiology: Oral Glycoprotein IIb/IIa Antagonists: 8, 26 Aug 1997Google Scholar
  18. 18.
    Kereiakes DJ, Kleiman NS, Ferguson JJ, et al. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial. Circulation 98: 1268–1278, 29 Sep 1998PubMedCrossRefGoogle Scholar
  19. 19.
    O’Neill WW. The evaluation of xemilofiban in controlling thrombotic events (EXCITE) trial: 30-day and six-month results. Journal of the American College of Cardiology 33 (Suppl. A): Feb 1999Google Scholar
  20. 20.
    Chew DP, Bhatt DL, Topol EJ. Increased mortality with oral glycoprotein IIb/IIIa antagonists: a pooled analysis of the large scale oral glycoprotein IIb/IIIa trials. Journal of the American College of Cardiology 35 (Suppl. A): 393, Feb 2000Google Scholar

Copyright information

© Adis Data Information BV 2003

Personalised recommendations